It is a fact; the pharmaceutical industry business model has been dramatically altered. The industry no longer relies exclusively upon blockbuster drugs to drive growth. There is an increasing reliance on small market drugs and a greater use of demographically focused packaging in order to cater to the child safe and senior friendly segments. The industry is in rapid transition from a supply-driven market to a demand and service-driven market where manufacturing efficiency and responsiveness plays a critical role in future success. While the new biological drugs are the future in driving revenue and margin growth in the business, the pharmaceutical industry needs to operate the traditional chemical drug business at peak efficiency. To remain successful, pharmaceutical companies must transform their chemical drug discovery business to a high quality, manufacturing, and global drug supply chain operation. There is a need to transform the current and future manufacturing to better compete with both generic and branded Rx competitors in their franchises. This will enable pharmaceutical companies to achieve their business objectives via entry into the generic drug manufacturing business and move branded non-Rx drugs to OTC.

Reprinted with Permission from www.systech-tips.com